These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4698260)

  • 1. N-hexyl-O-glucosyl sphingosine, an inhibitor of glucosyl ceramide -glucosidase.
    Erickson JS; Radin NS
    J Lipid Res; 1973 Mar; 14(2):133-7. PubMed ID: 4698260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites.
    Osiecki-Newman K; Fabbro D; Legler G; Desnick RJ; Grabowski GA
    Biochim Biophys Acta; 1987 Sep; 915(1):87-100. PubMed ID: 2956992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.
    Gatt S; Dinur T; Osiecki K; Desnick RJ; Grabowski GA
    Enzyme; 1985; 33(2):109-19. PubMed ID: 3924590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of N-hexyl-O-glucosyl sphingosine on normal cultured human fibroblasts: a chemical model for Gaucher's disease.
    Warren KR; Schafer IA; Sullivan JC; Petrelli M; Radin NS
    J Lipid Res; 1976 Mar; 17(2):132-8. PubMed ID: 178814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human acid beta-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites.
    Osiecki-Newman K; Legler G; Grace M; Dinur T; Gatt S; Desnick RJ; Grabowski GA
    Enzyme; 1988; 40(4):173-88. PubMed ID: 3234317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined gas chromatography-chemical ionization mass spectrometry of sphingolipids. I. Glucosyl sphingosine, ceramides and cerebrosides of the spleen in Gaucher's disease.
    Oshima M; Ariga T; Murata T
    Chem Phys Lipids; 1977 Aug; 19(4):289-99. PubMed ID: 908103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathic Gaucher's disease with normal 4-methylumbelliferyl-beta-glucosidase activity in the liver.
    Owada M; Sakiyama T; Kitagawa T
    Pediatr Res; 1977 May; 11(5):641-6. PubMed ID: 870871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrolytic and transglucosylation activities of a purified calf spleen beta-glucosidase.
    Kanfer JN; Raghavan SS; Mumford RA
    Biochim Biophys Acta; 1975 May; 391(1):129-40. PubMed ID: 237551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The occurrence of beta-glucocerebrosidase activity in the glucocerebroside-rich deposits of Gaucher's disease.
    Glew RH; Christopher AR; Schnure FW; Lee RE
    Arch Biochem Biophys; 1974 Jan; 160(1):162-7. PubMed ID: 4364062
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitors of beta-glucosidases of animal tissues.
    Radin NS
    Adv Exp Med Biol; 1978; 101():589-600. PubMed ID: 96666
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of beta-glucosidase by N-(n-hexyl)-O-glucosylsphingosine in cell strains of neurological origin.
    Dawson G; Stoolmiller AC; Radin NS
    J Biol Chem; 1974 Jul; 249(14):4638-46. PubMed ID: 4858402
    [No Abstract]   [Full Text] [Related]  

  • 12. Acid beta-glucosidase and the diagnosis of Gaucher's disease in liver and spleen.
    Butterworth J; Broadhead DM
    Clin Chim Acta; 1978 Aug; 87(3):433-40. PubMed ID: 28186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A kinetic study of the effects of galactocerebroside 3-sulphate on human spleen glucocerebrosidase. Evidence for two activator-binding sites.
    Prence EM; Garrett KO; Glew RH
    Biochem J; 1986 Aug; 237(3):655-62. PubMed ID: 3800908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human lysosomal beta-glucosidase: kinetic characterization of the catalytic, aglycon, and hydrophobic binding sites.
    Grabowski GA; Gatt S; Kruse J; Desnick RJ
    Arch Biochem Biophys; 1984 May; 231(1):144-57. PubMed ID: 6426391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE.
    BRADY RO; KANFER J; SHAPIRO D
    J Biol Chem; 1965 Jan; 240():39-43. PubMed ID: 14253443
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of rates of hydrolysis of N-oleoyl and N-stearoyl glucocerebroside in patients with Gaucher's disease.
    Peters SP; Aquino L; Naccarato WF; Gilbertson JR; Diven WF; Glew RH
    Biochim Biophys Acta; 1979 Oct; 575(1):27-36. PubMed ID: 508779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human acid beta-glucosidase: use of sphingosyl and N-alkyl-glucosylamine inhibitors to investigate the properties of the active site.
    Greenberg P; Merrill AH; Liotta DC; Grabowski GA
    Biochim Biophys Acta; 1990 May; 1039(1):12-20. PubMed ID: 2141287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of glucosylsphingosine from Gaucher's spleen.
    Raghavan SS; Mumford RA; Kanfer JN
    J Lipid Res; 1974 Sep; 15(5):484-90. PubMed ID: 4414001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher's disease.
    Basu A; Prence E; Garrett K; Glew RH; Ellingson JS
    Arch Biochem Biophys; 1985 Nov; 243(1):28-34. PubMed ID: 3933429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and properties of a heat-stable glucocerebrosidase activating factor from control and Gaucher spleen.
    Peters SP; Coyle P; Coffee CJ; Glew RH
    J Biol Chem; 1977 Jan; 252(2):563-73. PubMed ID: 13071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.